Guidance

International Council for Harmonisation (ICH) E6R3 Annotationsannotations

Information to help comply with ICH E6(R3),guidelines, if you are running clinical trials in the UK.

Documents

Details

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)(ICH)  has produced Guidelinea forseries Goodof international Clinicalguidelines concerning the Practicedesign, isconduct, safety and anreporting international guideline that has been developed to facilitate the harmonisation of the quality of the conduct of clinical trialstrials (the thatEfficacy are intended to be submitted to a regulatory authority in one or more ICH regions to gain a marketing authorisation approval (MAA) for a medicinal product.guidelines).  

In places,places, these ICHguidelines include references E6(R3) includes references to “applicable regulatory requirements”requirements” or insimilar in the relevant ICH region. ThisThe documents documentlinked ison intendedthis page are intended to support those involved in running clinical trials in the UK toto comply complywith the ICH Efficacy withguidelines by ICH E6(R3) by specifying what the applicable regulatory requirements or relevant guidance documents are for the UK.

Updates to this page

Published 12 January 2026
Last updated 9 March 2026 href="#full-history">+ show all updates
  1. On the document 'UK-specific annotations to ICH E6(R3)': added reference to ICH E8. Added annotation to Annex 1 2.6.4; updated annotation to Annex 1 2.13 and Annex 3.17.2 (c)(iii) to include reference to HRA guidance on research transparency; updated annotation to Annex 3.17.2 (c)(ii) to clarify that action should be taken in accordance with the protocol. Added document 'UK-specific annotations to ICH E8'.

  2. First published.

Sign up for emails or print this page